Kantonsspital St.Gallen

Novartis LMB763

Roman Stillhard & David Semela

abstract A randomized, patient and investigator blinded, placebo-controlled, multicentre study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (NASH)
type of project clinical studies
status completed
start of project 2017
end of project 2019
responsible person PD Dr. Dr. David Semela